The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China

Vaccine

Volumn 33, Issue 23, 2015, Pages 2704-2709

  Wang, Feng ^a   Shen, Liping ^a   Cui, Fuqiang ^a   Zhang, Shuang ^a   Zheng, Hui ^a   Zhang, Yong ^a   Liang, Xiaofeng ^a   Wang, Fuzhen ^a   Bi, Shengli ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Hepatitis B vaccination; Hepatitis B virus; Long term efficacy

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ARTICLE; BLOOD SAMPLING; CHINA; CROSS-SECTIONAL STUDY; EVALUATION STUDY; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; PREVALENCE; PRIORITY JOURNAL; VACCINATION; ADOLESCENT; ADULT; CHILD; ENDEMIC DISEASE; FEMALE; HEPATITIS B; IMMUNOLOGY; INFANT; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHINA; CROSS-SECTIONAL STUDIES; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 84929048371     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.064     Document Type: Article

References (22)

1. World Health Organization Hepatitis B 2000, World Health Organization, Geneva, Switzerland, http://www.who.Int/mediacentre/factsheets/fs204/en [accessed 02.06.10].
2. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
3. Dai Z.C., Qi G.M. Viral Hepatitis in China sero-epidemiological survey in Chinese population (part one) 1995, 39-58. Beijing Science and Technology Document Press.
4. Xia G.L., Liu C.B., Cao H.L., Bi S.L., Zhan M.Y., Su C.A., et al. Prevalence of hepatitis and virus infections in the general Chinese population. Results from nationwide cross-sectional seroepidemiologic study of hepatitis A: B, C, and virus infections in China, 1992. Int Hepatol Commun 1996, 5(1):62-73.
5. Progress in hepatitis B prevention through universal infant vaccination China, 1997-2006. Morb Mortal Wkly Rep 2007, 56(18):441-445.
6. Liu C.B., Su C.A. The immunization of hepatitis B vaccine and its problems. Chin J Vac Immun 2004, 10(3):159-162.
7. Shen L.P., Zhang Y., Wang F., Zhang S., Yang J.Y., Fang K.X., et al. Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme. Epidemiol Infect 2011, 139(8):1159-1165.
8. Liang X.F., Bi S.L., Yang W.Z., Wang L.D., Cui G., Cui F.Q., et al. Epidemiological serosurvey of hepatitis in China declining HBV prevalence due to hepatitis vaccination. Vaccine 2009, 27(47):6550-6557.
9. Wu Q., Zhuang G.H., Wang X.L., Wang L.R., Li N., Zhang M. Antibody levels and immune memory 23 years after primary plasma-derived hepatitis B vaccination: results of a randomized placebo-controlled trial cohort from China where endemicity is high. Vaccine 2011, 29(47):2302-2307.
10. Shen L.P., Wang F.Z., Wang F., Cui F.Q., Zhang S., Zheng H., et al. Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China. Vaccine 2012, 30:6623-6627.
11. Liu C.B., Xu Z.Y., Cao H.L. Sero-epidemiology of HBV infection in four province in China. Chin J Virol 1991, 7(Suppl.):8-14.
12. Shen L.P., Yang J.Y., Mo Z.J. Study on the variations of hepatitis B virus status among people having received hepatitis B vaccine. Chin J Epidemiol 2007, 28:659-662.
13. Huang M.J., Fu T.Y., Xu Z.Y. The survey about the prevalence of hepatitis B virus. Shanghai J Prevent Med 1989, 1:16217.
14. Young B.W., Lee S.S., Lim W.L. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. J Viral Hepat 2003, 10:23-30.
15. Watson B., West D.J., Percy S. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine 2001, 19:3164-3168.
16. Wasley A., Kruszon-Moran D., Kuhnert W. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010, 202:192-201.
17. Sun Y.D., Xie Y.F., Ma J.C. The prevalence of HBV markers in country area in Hebei, China. Chin J Epidemiol 1987, 8:70-74.
18. Han C.Q., Ma J.C., Liu H.B. 8-year study on efficacy of hepatitis vaccine in Zhengding County after integrated it into EPI program. Chin Clin Exp Virol 1995, 9:51-54.
19. Tian C., Ma J.C., Han C.Z. Infective status of HBV among population after 19 years immunization. Chin Vaccines Immun 2007, 13:4-7.
20. Ding Y., Sheng Q., Ma L. Chronic HBV infection among pregnant women and their infants in Shenyang, China. Virol J 2013, 7:10-17.
21. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. comprehensive immunization strategy to eliminate transmission of hepatitis virus infection in the United States recommendations of the Advixory Committee on Immunizaton Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Morb Mortal Wkly Rep 2005, 54(RR16):1-27.
22. Kaoa J., Wang J.H., Hung C.H., Yen Y.H., Hung S.F., Hu T.H., et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009, 27:1858-1862.